We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Biospecimen and Clinical Data Study on Patients With Alzheimer's, Multiple Sclerosis, Parkinson's, and Huntington's, for Drug & Biomarker Discovery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01592552
Recruitment Status : Completed
First Posted : May 7, 2012
Last Update Posted : April 8, 2019
Sponsor:
Information provided by (Responsible Party):
Sanguine Biosciences

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this research project is to collect and store blood samples and clinical data. Researchers can then use the stored samples in future studies. Through such studies, they hope to find new ways to detect, treat, and maybe even prevent or cure health problems.

Condition or disease
Alzheimer's Disease Multiple Sclerosis Parkinson's Disease Huntington's Disease Amyotrophic Lateral Sclerosis (ALS)

Detailed Description:
Blood samples are collected in the comfort and safety of your home by a certified medical professional. We have mobile phlebotomists located in major metropolitan areas around the nation for your convenience.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 20 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: A Multi-Center Longitudinal Biorepository Study to Provide Biospecimens & Clinical Data From Neurological Disease Patients To Approved Pre-Clinical And Clinical Investigators for Drug & Biomarker Studies
Study Start Date : November 2011
Actual Primary Completion Date : March 2015
Actual Study Completion Date : March 2015

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
Neurological Condition
Collect blood and other biospecimens like saliva, urine and CSF for research purposes.
Control
Collect blood and other biospecimens like saliva, urine and CSF for research purposes.


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Biospecimens & Clinical Data collection from patients with neurological diseases. [ Time Frame: 2 years ]
    The purpose of this research project is to collect and store blood samples and clinical data. Researchers can then use the stored samples in future studies. Through such studies, they hope to find new ways to detect, treat, and maybe even prevent or cure health problems.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
A diagnosis of Multiple Sclerosis, Alzheimer's, Huntington's, or Parkinson's Disease.
Criteria

Inclusion Criteria:

  • Males and females >18 to 100 years old
  • A diagnosis of neurological condition
  • Proof of diagnosis can be provided

Control group: Healthy donors, males and females, 18 to 100 years of age

Exclusion Criteria

  • Receipt of blood products within 30 days of study enrollment
  • Receipt of an investigational (unapproved) drug within 30 days of study enrollment
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01592552


Locations
Layout table for location information
United States, California
Sanguine Biosciences
Sherman Oaks, California, United States, 91403
Sponsors and Collaborators
Sanguine Biosciences
Investigators
Layout table for investigator information
Principal Investigator: Phil Silkoff, MD Sanguine Biosciences
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Sanguine Biosciences
ClinicalTrials.gov Identifier: NCT01592552    
Other Study ID Numbers: SAN-ND-01
First Posted: May 7, 2012    Key Record Dates
Last Update Posted: April 8, 2019
Last Verified: April 2019
Keywords provided by Sanguine Biosciences:
Alzheimer's Disease
Multiple Sclerosis
Parkinson's Disease
Huntington's Disease
Amyotrophic Lateral Sclerosis (ALS)
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Multiple Sclerosis
Alzheimer Disease
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Huntington Disease
Sclerosis
Pathologic Processes
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Synucleinopathies
 Neurodegenerative Diseases
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Dementia
Tauopathies
Neurocognitive Disorders
Mental Disorders
Neuromuscular Diseases
Spinal Cord Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases